Ultragenyx Pharmaceutical (RARE) Shares Down 6.4%
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) traded down 6.4% during mid-day trading on Friday . The company traded as low as $64.56 and last traded at $64.65. 630,416 shares traded hands during trading, a decline of 5% from the average session volume of 664,786 shares. The stock had previously closed at $69.04.
A number of equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday, March 15th. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Cowen reiterated a “buy” rating and set a $69.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 26th. Raymond James reiterated an “outperform” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 22nd. Finally, Citigroup increased their target price on shares of Ultragenyx Pharmaceutical from $54.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. Six research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Ultragenyx Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $76.16.
The stock has a market cap of $3.54 billion, a P/E ratio of -8.75 and a beta of 2.21.
In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 14,800 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $70.00, for a total value of $1,036,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.40% of the company’s stock.
Several large investors have recently made changes to their positions in the business. Alliancebernstein L.P. grew its position in shares of Ultragenyx Pharmaceutical by 5.4% in the 3rd quarter. Alliancebernstein L.P. now owns 992,357 shares of the biopharmaceutical company’s stock valued at $75,757,000 after buying an additional 50,489 shares during the last quarter. Capital Impact Advisors LLC grew its position in shares of Ultragenyx Pharmaceutical by 31.7% in the 4th quarter. Capital Impact Advisors LLC now owns 37,858 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 9,112 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Ultragenyx Pharmaceutical by 5.3% in the 3rd quarter. Wells Fargo & Company MN now owns 23,742 shares of the biopharmaceutical company’s stock valued at $1,812,000 after buying an additional 1,194 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $1,954,000. Finally, Kiwi Wealth Investments Limited Partnership purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $958,000. 97.80% of the stock is currently owned by institutional investors.
About Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Featured Article: Blue-Chip Stocks
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.